In today’s ACT Brief, we look at new evidence showing how targeted training can build research readiness at community cancer ...

Discover how remote assessments, wearables, and digital technologies can decentralize data collection, reduce patient burden, and enable trials to reach more diverse and representative populations.

And the FDA has approved Amgen’s Uplizna for adults with antibody-positive generalized myasthenia gravis, adding a ...

Explore how expanding clinical trials into community and nontraditional sites, simplifying protocols, and leveraging AI can ...

See how combining human oversight with AI insights improves protocol authorship, site selection, and monitoring strategies, ...

In today’s ACT Brief, we break down FDA’s new superiority requirement reshaping CAR-T development, examine Pfizer’s global ...

For industry-sponsored trials in autoimmune inflammation therapeutic areas, the dominating indications include atopic ...

Explore how AI can optimize study design, speed patient recruitment, and streamline operational workflows to shorten ...

This pilot project evaluated whether targeted training could strengthen clinical research capacity at community cancer centers, improve readiness to conduct oncology trials, and support more inclusive ...

As highly effective anti-obesity therapies emerge and regulatory expectations evolve, sponsors are adopting innovative trial designs, addressing long-term weight maintenance, monitoring lean mass ...

Strong relational governance between technology vendors and sponsor–CRO teams is becoming a critical foundation for eCOA ...

ACT: As new ICH GCP guidelines roll out, how are sponsors balancing the drive for innovation—especially in areas like CAR-T ...